ORYZON expands global patent protection for iadademstat with grant decision in Japan covering combinations with PD-1/PD-L1 inhibitors

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. 

Following formal grant, the patent is expected to remain in force until at least 2040, excluding any available patent term extensions. With this decision, Oryzon has now secured patent protection for these combinations in Europe, Japan, Australia and Russia, while corresponding patent applications continue to be prosecuted in other countries. 

“This Japanese grant represents another important milestone in building a robust patent portfolio around iadademstat,” said Neus Virgili, Oryzon’s Chief IP Officer. “It reinforces our strategy to protect the clinical use of iadademstat in combination with immune checkpoint inhibitors such as atezolizumab and durvalumab in small cell lung cancer (SCLC), an approach we are evaluating as part of iadademstat’s ongoing clinical development programs.”

Iadademstat is being evaluated in combination with PD-L1 inhibitors (atezolizumab or durvalumab) in first line, extensive-disease SCLC patients in an ongoing Phase I/II trial conducted and sponsored by the U.S. National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon. The study is carried out at more than 30 clinical sites across the United States, including leading cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins, City of Hope, Yale University and the University of Chicago, among others.